Introduction
============

MicroRNAs (miRNAs) are a class of small non-coding RNAs (length, \~22 nt) that regulate gene expression at the post-transcriptional levels. miRNAs are involved in the regulation of the majority of important biological events, including differentiation, growth, proliferation, survival, signal transduction and immune response ([@b1-mmr-13-06-4969]--[@b3-mmr-13-06-4969]). However, the roles of miRNAs in regulating the activation of human bone marrow-derived mesenchymal stromal cells (BM-MSCs) remain to be elucidated.

The BM-MSCs are multipotent cells that differentiate into osteoblasts, adipocytes, chondrocytes and other tissue cells ([@b4-mmr-13-06-4969]--[@b7-mmr-13-06-4969]). It has been demonstrated that toll-like receptors (TLRs) are expressed in MSCs to modulate their proliferation, cytokine secretion, differentiation, hematopoiesis-supporting functions and immunosuppressive capacity ([@b8-mmr-13-06-4969]--[@b10-mmr-13-06-4969]). Notably, it is well established that TLRs induce multiple miRNAs, which regulate TLR-signaling responses at multiple levels. For example, TLR2 and TLR4 are repressed by expression of miR-105, miR-146 and the let-7 miRNA family ([@b11-mmr-13-06-4969]--[@b14-mmr-13-06-4969]). However, miR-155 and miR-146b directly target numerous TLR signaling proteins ([@b15-mmr-13-06-4969],[@b16-mmr-13-06-4969]). Regulatory molecules, TLR-induced transcription factors and the inflammatory cytokines are also regulated by miRNAs, including miR-155 ([@b17-mmr-13-06-4969]).

It has previously been verified that pre-stimulation with the TLR2 agonist, PAM~3~CSK4 (PM) or the TLR4 agonist, lipopolysaccharides (LPS) enables BM-MSCs to enhance CD34^+^ cell proliferation and differentiation towards the myeloid lineage ([@b10-mmr-13-06-4969]). To further elucidate the roles of miRNAs in mediating TLR-induced BM-MSC activation, the present study aimed to determine the miRNA expression profiles in unstimulated BM-MSCs and PM/LPS-stimulated BM-MSCs, using high-throughput Illumine HiSeq 2000 technology. Bioinformatic methods were also used to predict the potential target genes of the abundant known miRNAs. Furthermore, data from the present study indicated that miRNAs are involved in various important functions in human BM-MSCs, including the TLR signaling pathway.

Materials and methods
=====================

Isolation and culture of BM-MSCs
--------------------------------

BM-MSCs were isolated from fresh bone marrow by sterile puncture of a healthy donor. The present study was approved by the Anhui Medical University Ethics Committee, and informed written consent was obtained from the donor. The isolation, expansion and identification of BM-MSCs were performed as described previously ([@b10-mmr-13-06-4969]). Briefly, following density gradient centrifugation over Ficoll-Hypaque (1.077 g/ml; Beijing Solarbio Science &Technology Co., Ltd., Beijing, China), BM-MSCs were cultured (1×10^6^ cells/ml) in Dulbecco\'s High Glucose Modified Eagles Medium (GE Healthcare Life Sciences, Logan, UT, USA), supplemented with 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and containing 5% CO~2~ at 37°C. Non-adherent cells were removed after 24 h and the culture medium was changed twice a week. Adherent cells were cultured until 80--90% confluence was reached, after which trypsin (0.25%; Gibco) digestion was conducted on passage three cells. BM-MSCs were analyzed by flow cytometry (FACSCalibur™; BD Biosciences, Franklin Lakes, NJ, USA) following staining with monoclonal antibodies, as follows: Fluorescein isothiocyanate (FITC)-conjugated anti-cluster of differentiation (CD) 90 (1:10; cat. no. 555595); FITC-anti-CD14 (1:10; cat. no. 555397), phycoerythrin (PE)-anti-CD29 (cat. no. 555443), cyanine5-PE-anti-CD34 (cat. no. 555823), PE-anti-CD166 (cat. no. 559263), FITC-anti-CD44 (1:10; cat. no. 555478), PE-anti-CD31 (1:10; cat. no. 560983), FITC-anti-CD45 (1:10; cat. no. 555482), PE-anti-CD13 (1:10; cat. no. 560998) and FITC-anti-CD105 (1:10; cat. no. 561443; all: BD Biosciences). BM-MSCs were confirmed by negative staining of hematopoietic and endothelial lineage markers (CD14, CD34, CD31 and CD45) and positive staining of CD90, CD105, CD166, CD29, CD44 and CD13.

PM and LPS stimulation
----------------------

LPS (100 ng/ml) and PM (100 ng/ml) were purchased from R&D Systems, Inc. (Minneapolis, Minnesota, USA). The BM-MSC feeder layers in 12-well plates were stimulated with (experimental group) or without (control) TLR2 agonist, PM, or TLR4 agonist, LPS, for 24 h. The supernatants were removed and the feeder layers were washed twice with fresh culture medium.

Total RNA extraction and small RNA sequencing library preparation
-----------------------------------------------------------------

Total RNA was isolated from confluent MSCs with TRIzol (Promega Corporation, Madison, WI, USA). The purity and concentration of total RNA samples were determined with NanoDrop ND-1000 (Thermo Fisher Scientific, Inc., Wilmington, DE, USA). Total RNA of each sample was used to prepare the miRNA sequencing library using the TruSeq Small RNA Library Prep kit (RS-200-0012; Illumina, Inc., San Diego, CA, USA), according to the manufacturer\'s protocol. This included the following steps: i) 3′-Adapter ligation with truncated T4 RNA ligase 2 (New England BioLabs, Inc., Ipswich, MA, USA); ii) 5′-adapter ligation with T4 RNA ligase (Ambion; Thermo Fisher Scientific, Inc.); iii) cDNA synthesis with reverse transcription primers (Bioligo Biological Technology, Co., Ltd., Shanghai, China); iv) polymerase chain reaction (PCR) amplification; and v) extraction and purification of PCR amplified fragments \[length,\~138--158 bp; corresponding to small RNAs (length,\~15--35 nt)\] from the agarose gel. Subsequently, the completed libraries were quantified with an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA).

Small RNA sequencing
--------------------

The samples were diluted to a final concentration of 8 pM and cluster generation was performed on the Illumina cBot using TruSeq Rapid SR cluster kit (Illumina, Inc.), following the manufacturer\'s protocols. Sequencing was performed on an Illumina HiSeq 2000 using TruSeq Rapid SBS kits (Illumina, Inc.), according to the manufacturer\'s protocols. The DNA fragments in the libraries were denatured with 0.1 M NaOH to generate single-stranded DNA molecules, captured on flow cells (Illumina, Inc.), amplified *in situ* and finally sequenced for 36 cycles on Illumina HiSeq 2000.

Analysis of sequencing data and length distribution
---------------------------------------------------

Using high throughput sequencing with an Illumina Hiseq 2000, total clean reads from the control and trial libraries were obtained, and the length distribution of the clean reads was summarized. Image analysis and base calling were performed using Off-Line Basecaller software (v1.8.0; Illumina, San Diego, CA, USA). Subsequently, the 3′-adapter sequence was trimmed from the clean reads \[that had passed the Solexa CHASTITY quality filter (Illumina)\] and the reads of length \<15 nt were discarded. Remaining reads (length, ≥15 nt) were aligned to the latest known human reference miRNA precursor set \[Sanger miRBase 19 (<http://www.mirbase.org/>)\] using Novoalign software (v2.07.11; <http://www.novocraft.com/products/novoalign/>). Reads (\<2 counts) were discarded when calculating the miRNA expression. In order to characterize the isomiR variability, any sequence that matched the miRNA precursors in the mature miRNA region ±4 nt (with ≤1 mismatch) were accepted as mature miRNA isomiRs, which were grouped according to the 5-prime (5p) or 3-prime (3p) arm of the precursor hairpin.

Prediction of novel miRNAs
--------------------------

miRDeep2 (<http://www.mdc-berlin.de/en/research/research_teams/systems_biology_of_gene_regulatory_elements/projects/miRDeep>) was used to predict novel miRNAs. For novel miRNA prediction, all sequence data was pooled from the following 3′-adapter trimmed files: LPS, PM and contrimmed_tags.fa, all adapter trimmed sequences of length \<17 bp and mismatch \>1 were excluded from the prediction pipeline. The higher the novel miRNA score of the miRDeep2, the more reliable the novel miRNA was considered to be.

Target gene prediction
----------------------

Three online search algorithms, TargetScan version 6.2 (<http://www.targetscan.org/vert_60/>) and miRanda (<http://www.Microrna.org/microrna/home.do>) and MicroCosm Targets version 5 (<http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/>) were used to predict the target genes of differentially expressed (DE) miRNAs among the BM-MSCs activated with the TLR2 and TLR4 agonists, and BM-MSCs in the absence of agonists. The annotated miRNA target genes that were selected from all the algorithms were considered to be the target genes.

Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of the predicted miRNA target genes
--------------------------------------------------------------------------------------------------------------------------

In order to further realize the functions, the predicted target genes were subjected to the analysis of GO project (<http://www.geneontology.org>). Fisher\'s exact test was used to find whether there was increased overlap between the DE list and the GO annotation list than would be expected by chance. The P-value denotes the significance of GO term enrichment in the DE genes; the lower the P-value, the more significant the GO term (P\<0.05 is recommended). Furthermore, pathway analysis was performed for these target genes. Pathway analysis is a functional analysis that maps genes to the KEGG pathways. The P-value (EASE-score, Fisher\'s method P-value or hypergeometric P-value) indicates the significance of the pathway correlated to the conditions. A lower P-value, indicates a more significant pathway (P\<0.05 is recommended).

Validation of miRNA expression by quantitative PCR (qPCR)
---------------------------------------------------------

A random selection of DE miRNAs between the experimental and control groups from the sequencing data was validated by qPCR. Corroboration of the six novel miRNAs was performed according to the previously described conditions using qPCR assays. Total RNA was isolated from each sample using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The miRNA quantification was performed by qPCR using Applied Biosystems StepOne Real-Time PCR system (Thermo Fisher Scientific, Inc.) and SYBR premix Ex Taq II kit (Takara Bio, Inc.) according to the manufacturer\'s protocols. U6 served to normalize the levels of all miRNA transcripts, the primer sequences were forward, 5′-GCT TCG GCA GCA CAT ATA CTA AAAT-3′ and reverse, 5′-CGC TTC ACG AAT TTG CGT GTCAT-3′ for U6. Relative expression of miRNA was evaluated by the 2^−ΔΔCq^ method ([@b18-mmr-13-06-4969]). All miRNA samples and the internal reference U6 were run in a qPCR reaction. Thermal cycling conditions of the qPCR were 95°C for 10 min; 40 cycles of 95°C for 10 sec; and 40 cycles of 60°C for 60 sec.

Results
=======

Overview of LPS and PM-induced miRNA expression profiling
---------------------------------------------------------

To obtain a comprehensive view of the miRNA profile of BM-MSCs stimulated with LPS and PM, Illumine HiSeq 2000 technology was used to detect the global expression level annotated in Sanger miRBase 19.0. A total of 67 miRNAs demonstrated different expression patterns between the LPS and control groups (BM-MSCs without stimulation), with 32 downregulated miRNAs ([Table I](#tI-mmr-13-06-4969){ref-type="table"})and 35 upregulated miRNAs ([Table II](#tII-mmr-13-06-4969){ref-type="table"}). In PM-treated cells, the downregulation ([Table III](#tIII-mmr-13-06-4969){ref-type="table"}) and upregulation ([Table IV](#tIV-mmr-13-06-4969){ref-type="table"}) were observed for 51 and 46 miRNAs, respectively. To assess the sequencing quality, the length distribution of the clean reads was summarized. Few differences were observed in the length distribution of the sequences from the control and trial libraries ([Fig. 1](#f1-mmr-13-06-4969){ref-type="fig"}). The most abundant sequence reads were 22, 23, 21 and 24 nt in length, which is consistent with the typical small RNA distribution of mammals.

qPCR verification of known miRNAs
---------------------------------

For identification of the authenticity of the miRNAs detected by Illumine HiSeq 2000 technology, 40 known miRNAs from [Tables I](#tI-mmr-13-06-4969){ref-type="table"}--[IV](#tIV-mmr-13-06-4969){ref-type="table"} were randomly selected for further validation with additional samples by qPCR. As presented in [Fig. 2](#f2-mmr-13-06-4969){ref-type="fig"}, the qPCR data were highly consistent with Illumine HiSeq 2000 technology, confirming the reliability of the HiSeq 2000 sequencing data.

Novel miRNA identification
--------------------------

To identify the novel, unannotated miRNAs in human BM-MSCs, the unlabeled reads were analyzed by miRDeep2. The present study focused on six potential novel miRNAs with the most frequent appearance among all the samples and the highest miRDeep2 score. The expression levels of these six miRNAs were further validated by qPCR. Compared with Illumine HiSeq 2000 sequencing, qPCR indicated the same trend of expression levels for the six novel miRNA candidates ([Fig. 3](#f3-mmr-13-06-4969){ref-type="fig"}).

Predicted target genes of LPS- and PM-responsive miRNAs
-------------------------------------------------------

To characterize the DE miRNAs between LPS, PM and the controls, the target genes of the DE miRNAs were predicted using three different miRNA target prediction algorithms (TargetScan, MicroCosm and miRanda). Subsequently, the target genes that were identified in all three databases underwent GO analysis. In the LPS group, the targets genes of downregulated miRNAs were significantly enriched in transcripts from the RNA polymerase II promoter and included regulation of macromolecule metabolic processes, gene expression and nucleobase-containing compound metabolic processes; the most enriched GO terms of targets genes of upregulated miRNAs included anatomical structure morphogenesis, regulation of cellular processes, biological processes and cell development. In the PM group, significantly enriched GO terms of targets genes of down-regulated miRNAs included regulation of biological process, system development, transcription from RNA polymerase II promoter and cell differentiation; the most enriched GO terms of targets genes of downregulated miRNAs included regulation of signal transduction, cellular process, cell communication and biological process ([Fig. 4](#f4-mmr-13-06-4969){ref-type="fig"}). KEGG pathway analysis indicated that the predicted target genes were significantly enriched in a wide range of pathways. LPS-regulated miRNAs predominantly target mitogen activated protein kinases (MAPKs), estrogen, T cell receptors, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3)-Akt, the mammalian target of rapamycin signaling pathway and cancer-associated signaling pathways, while PM-regulated miRNAs target the P13-Akt, ras-related protein 1, neurotrophin, MAPK and Ras signaling pathways ([Fig. 5](#f5-mmr-13-06-4969){ref-type="fig"}).

Discussion
==========

A number of studies have reported the expression of TLRs upon MSC and TLR activation in MSCs regulates their functions in immunomodulation, migration, repair and regeneration of damaged tissues/organs ([@b19-mmr-13-06-4969]--[@b24-mmr-13-06-4969]). In addition, a previous study reported that TLR2 agonists (PM) and/or TLR4 agonists (LPS) were able to activate MSCs, thus modulating their hematopoiesis-supporting role *in vitro* ([@b10-mmr-13-06-4969]). The present study hypothesized that the miRNAs induced by TLR activation may control MSC processes, including immunomodulation, migration, and repair and regeneration of damaged tissues/organs. The present study analyzed the differential miRNA expression profiles in the MSCs derived from human fresh bone marrow and stimulated with LPS or PM. By high-throughput sequencing, compared with the expression levels in unstimulated MSCs, 67 miRNAs were identified with 35 miRNAs upregulated and 32 downregulated following LPS stimulation; 97 miRNAs with 46 miRNAs upregulated and 51 downregulated following PM stimulation. Data from the present study demonstrated that the responses to LPS or PM prompted quick and specific *in vitro* alterations to the miRNA expression profile of BM-MSCs.

miR-425, which has been demonstrated to be DE and the most markedly downregulated, was observed in the LPS and PM-stimulated BM-MSCs. It was reported that upregulated expression of miR-425 was associated with a variety of types of cancer, including renal and gastric cancers ([@b25-mmr-13-06-4969],[@b26-mmr-13-06-4969]). A recent study demonstrated that nuclear factor-κB (NF-κB)-dependent miR-425 upregulation promotes gastric cancer cell growth by targeting phosphatase and tensin homolog in response to IL-1β treatment ([@b25-mmr-13-06-4969],[@b26-mmr-13-06-4969]). Furthermore, this indicates that the action of miR-425 may mediate cell proliferation. However, to the best of our knowledge, there are no reports investigating the effects of miR-425 in BM-MSCs. Compared with previous studies, the marked difference in expression level of miR-425 indicates that miRNAs may respond differently in LPS or PM-stimulated BM-MSCs and exert different effects in the different groups.

In accordance with the miRNA results demonstrating upregulation of miR-199a in human BM-MSCs during osteoblastic differentiation and chondrogenesis ([@b27-mmr-13-06-4969]), the most abundantly expressed miRNA in LPS-stimulated BM-MSCs was miR-199a, which was also upregulated in LPS-stimulated leukocytes derived from cord blood (CB) ([@b28-mmr-13-06-4969]). Laine *et al* ([@b27-mmr-13-06-4969]) demonstrated that cells transfected with pre-miR-199a reduced the proliferation of human MSCs and miR-199a restricts chondrogenic differentiation by suppressing the expression of SRY-box 9, which is a positive regulator of chondrogenesis ([@b29-mmr-13-06-4969]). In addition, miR-199a has been identified as a negative regulator of chondrogenesis ([@b30-mmr-13-06-4969]). Wu *et al* ([@b31-mmr-13-06-4969]) inferred that the overexpression of miR-199a-5p inhibits the proliferation of keloid fibroblasts. However, Shi *et al* ([@b32-mmr-13-06-4969]) demonstrated that overexpression of miR-199a-5p promoted the proliferation of porcine preadipocytes and suppressed adipogenic differentiation. These findings indicate that increased expression of miR-199a in LPS-stimulated BM-MSCs may be a key regulator for MSC differentiation and proliferation. As miR-199 was observed to exert opposing effects on proliferation in different cells, this is likely explained by miRNA-mRNA targeting, and the different interactions among tissue and cell types and physiological/pathological conditions ([@b33-mmr-13-06-4969]). Further studies are required to investigate the exact underlying mechanism of miR-199a action in BM-MSCs.

The miRNA that was most abundantly expressed in human PM-stimulated BM-MSCs was miR-214. Previous studies reported that miR-214 may be important in promoting myoblast proliferation and differentiation ([@b34-mmr-13-06-4969]); overexpression of miR-214 was connected to gastric cancer tissue, and deletion of miR-214 inhibited the proliferation, migration and invasion of gastric cancer cells ([@b35-mmr-13-06-4969]). The results are consistent with recent findings by Zhang *et al* ([@b36-mmr-13-06-4969]), that miR-214 is overexpressed in nasopharyngeal carcinoma tissues and cell lines, and that knockdown of miR-214 suppressed cell proliferation and induced apoptosis. However, Derfoul *et al* ([@b37-mmr-13-06-4969]), demonstrated that overexpression of miR-214 inhibited the proliferation and invasion of breast cancer cells. Thus, the abnormal expression of miR-214 may be closely associated with certain types of cancer by affecting cell growth, differentiation and migration.

However, whether the TLR signaling pathway is regulated by the above-mentioned miRNAs, which are expressed most differentially, and whether their target genes are involved in TLR signal transduction, requires further investigation.

To investigate the function of the LPS- or PM-induced DE miRNAs further, the target genes were predicted, and GO and KEGG pathway analyses were applied to these predicted target genes. The GO term annotation suggests that the presumed target genes of these DE miRNAs in BM-MSCs are involved in a broad range of physiological processes in response to stimuli. Consistent with the GO assay, among those pathways, the MAPK and PI3-Akt signaling pathway are notable, as they have been reported to be important in promoting cell proliferation, growth and differentiation ([@b38-mmr-13-06-4969]).

Notably, in the present study, a number of the verified TLR signaling pathway-associated miRNAs were markedly DE between the control and trial groups. For example, in the TLR4 agonist group, the associated markedly DE miRNAs were miR-146a, miR-155, miR-132, miR-29, miR-199a-5p, let-7b, miR-24, miR-221, miR-181, miR-106a/b, miR-20a, miR-26a and miR-34a ([@b14-mmr-13-06-4969],[@b15-mmr-13-06-4969],[@b39-mmr-13-06-4969]-[@b48-mmr-13-06-4969]). In the TLR2 agonist group, the associated markedly DE miRNAs were miR-146a/b, miR-155, miR-132, miR-29, miR-199a-3p, let-7b, miR-24, miR-221, miR-181, miR-106b, miR-92a, miR-210, miR-27b, miR-21, miR-125b, miR-101 and miR-148a/b ([@b12-mmr-13-06-4969],[@b15-mmr-13-06-4969],[@b16-mmr-13-06-4969],[@b38-mmr-13-06-4969]-[@b45-mmr-13-06-4969],[@b49-mmr-13-06-4969]-[@b54-mmr-13-06-4969]). These miRNAs in BM-MSCs may suggest a potentially important role in TLR signaling regulation. Furthermore, miR-146b was observed to be upregulated in CB leukocytes following LPS stimulation and may control LPS-stimulated neonatal early phases of inflammation via negative feedback loops ([@b28-mmr-13-06-4969]). Ma *et al* ([@b55-mmr-13-06-4969]) reported that miR-301a was upregulated in umbilical cord-MSCs stimulated with LPS, while miR-301a was not regulated by LPS and PM in the dataset produced in the present study, this notable difference is likely due to the different experimental methods and sources of material.

TLR activation triggers myeloid differentiation primary response gene 88-dependent and -independent downstream signaling cascades, leading to the activation of a number of transcription factors and genes ([@b56-mmr-13-06-4969]--[@b61-mmr-13-06-4969]). These downstream signaling molecules predominantly include transforming growth factor-β-activated kinase, IL-1R-associated kinases, MAPKs, NF-κB and tumor necrosis factor-receptor-associated factor 6 ([@b59-mmr-13-06-4969]). It has been demonstrated that following stimulation with ligands specific to TLRs, the NF-κB, MAPK, and PI3K signaling pathways were activated with a subsequent induction of multiple genes and cytokines ([@b62-mmr-13-06-4969]). Furthermore, combined with KEGG pathways analysis, the results of the present study indicate a critical role for miRNAs, via the TLR signaling pathway, in the growth, differentiation, and migration of LPS and PM-induced BM-MSCs.

During comparison of these two sets of experiments, a number of the TLR signaling pathway-associated miRNAs (miR-146a, miR-155, let-7b, miR-106b, miR-132, miR-29, miR-221 and miR-181) were found to be the same, and the up- or downregulation of specific miRNAs was also consistent, suggesting that LPS- or PM-induced miRNAs may have common targets and exert similar effects in BM-MSCs. Future studies are required to validate these predictions.

Six novel miRNAs that demonstrated marked changes in response to TLR activation were observed in the present study, which were not similar to any known miRNAs. Future investigations are required to predict and functionally validate these DE miRNA targets.

In conclusion, the results of the current study identify the global expression change of miRNAs in BM-MSCs stimulated with LPS and PM, providing a framework for further analysis of miRNAs and their role in mediating TLR signals to regulate the functions of BM-MSCs.
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![Confirmation of the differentially expressed miRNAs in PM or LPS stimulated bone marrow-derived mesenchymal stem cells and control groups. The expression of 10 miRNAs was validated by next-generation sequencing and quantitative PCR using differential expression patterns. The (A) increased and (B) decreased expression of miRNAs in the LPS group, and the (C) increased and (D) decreased expression miRNAs in the PM group. miRNA, microRNA; PCR, polymerase chain reaction; LPS, lipopolysaccharides; PM, PAM~3~CSK4.](MMR-13-06-4969-g01){#f2-mmr-13-06-4969}
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###### 

Enriched GO terms of biological processes, molecular functions and cellular components in predicted miRNA targets. Significantly enriched GO terms of target genes regulated by (A) increased and (B) decreased expression of miRNAs in the PAM~3~CSK4 group. GO, gene ontology; LPS, lipopolysaccharides; miRNA, microRNA. Enriched GO terms of biological processes, molecular functions and cellular components in predicted miRNA targets. Significantly enriched GO terms of target genes regulated by (C) increased and (D) decreased expression of miRNAs in the lipopolysaccharide group. GO, gene ontology; miRNA, microRNA.
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###### 

KEGG pathways of target genes demonstrating the greatest enrichment for differentially expressed miRNAs. The KEGG pathways enriched for target genes regulated by (A) increased and (B) decreased expression of miRNAs in the PAM~3~CSK4 group. KEGG, Kyoto Encyclopedia of Genes and Genomes; miRNA, microRNA; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; Rap-1, ras-related protein 1; HTLV, human T-lymphotropic virus; FoxO, forkhead box O. KEGG pathways of target genes demonstrating the greatest enrichment for differentially expressed miRNAs. The KEGG pathways enriched for target genes regulated by (C) increased and (D) decreased expression of miRNAs in the lipopolysaccharide group. KEGG, Kyoto Encyclopedia of Genes and Genomes; miRNA, microRNA; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; Rap-1, ras-related protein 1; HTLV, human T-lymphotropic virus; FoxO, forkhead box O.
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###### 

Downregulated miRs in bone marrow-derived mesenchymal stem cells stimulated with lipopolysaccharide.

  miR name          Fold change
  ----------------- -------------
  hsa-let-7a-3p     0.333333333
  hsa-miR-1         0.157248157
  hsa-miR-125a-5p   0.403608737
  hsa-miR-132-5p    0.161290323
  hsa-miR-137       0.253012048
  hsa-miR-154-3p    0.153846154
  hsa-miR-15a-5p    0.359223301
  hsa-miR-181a-5p   0.287637856
  hsa-miR-181c-3p   0.450000000
  hsa-miR-186-5p    0.128352490
  hsa-miR-199a-3p   0.309404320
  hsa-miR-199b-3p   0.309404320
  hsa-miR-221-3p    0.280632896
  hsa-miR-222-3p    0.374696936
  hsa-miR-24-3p     0.333686441
  hsa-miR-29a-3p    0.187765957
  hsa-miR-30d-5p    0.437901499
  hsa-miR-30e-5p    0.300376648
  hsa-miR-323a-3p   0.182186235
  hsa-miR-323b-3p   0.094527363
  hsa-miR-335-5p    0.413793103
  hsa-miR-337-3p    0.482758621
  hsa-miR-361-5p    0.454545455
  hsa-miR-369-3p    0.404193782
  hsa-miR-374a-5p   0.271111111
  hsa-miR-380-3p    0.400000000
  hsa-miR-411-3p    0.083179298
  hsa-miR-425-5p    0.016032811
  hsa-miR-450a-5p   0.183206107
  hsa-miR-708-5p    0.258064516
  hsa-miR-941       0.131578947
  hsa-miR-99b-5p    0.476327116

miR, microRNA.

###### 

Upregulated miRs in bone marrow-derived mesenchymal stem cells stimulated with lipopolysaccharide.

  miR name          Fold change
  ----------------- --------------
  hsa-let-7b-5p     2.918778428
  hsa-miR-100-5p    10.847709700
  hsa-miR-106a-5p   2.083333333
  hsa-miR-106b-5p   5.405405405
  hsa-miR-125a-3p   3.090909091
  hsa-miR-126-3p    2.282608696
  hsa-miR-128       10.200000000
  hsa-miR-136-3p    2.000000000
  hsa-miR-138-5p    15.218750000
  hsa-miR-146a-5p   2.125000000
  hsa-miR-155-5p    19.623376620
  hsa-miR-17-5p     5.828767123
  hsa-miR-18a-5p    4.888888889
  hsa-miR-199a-5p   32.703703700
  hsa-miR-20a-5p    4.294478528
  hsa-miR-218-5p    4.400000000
  hsa-miR-22-5p     2.133333333
  hsa-miR-224-5p    12.050000000
  hsa-miR-26a-5p    8.077169132
  hsa-miR-26b-5p    2.234290470
  hsa-miR-32-3p     2.750000000
  hsa-miR-34a-5p    2.252148997
  hsa-miR-3591-5p   3.214285714
  hsa-miR-361-3p    4.136363636
  hsa-miR-369-5p    2.222222222
  hsa-miR-424-3p    9.666666667
  hsa-miR-425-3p    3.461538462
  hsa-miR-455-3p    6.421052632
  hsa-miR-486-5p    3.418918919
  hsa-miR-497-5p    2.230769231
  hsa-miR-548d-5p   2.800000000
  hsa-miR-574-5p    7.185185185
  hsa-miR-7-5p      4.600000000
  hsa-miR-941       2.250000000
  hsa-miR-99a-5p    10.116279070

miR, microRNA.

###### 

Downregulated miRs in bone marrow derived mesenchymal stem cells stimulated with PAM~3~CSK4.

  miR name            Fold change
  ------------------- --------------
  hsa-let-7a-3p       0.339080460
  hsa-miR-1           0.090909091
  hsa-miR-101-3p      0.413533835
  hsa-miR-103a-3p     0.169556840
  hsa-miR-106b-3p     0.383177570
  hsa-miR-107         0.200000000
  hsa-miR-10a-5p      0.263522618
  hsa-miR-10a-3p      0.406250000
  hsa-miR-10b-5p      0.276625387
  hsa-miR-125b-5p     0.449112979
  hsa-miR-125b-1-3p   0.409638554
  hsa-miR-132-5p      0.322580645
  hsa-miR-134         0.266187050
  hsa-miR-137         0.409638554
  hsa-miR-140-5p      0.369565217
  hsa-miR-146b-5p     0.250539957
  hsa-miR-148a-5p     0.385714286
  hsa-miR-148b-5p     0.458333333
  hsa-miR-151a-3p     0.343228200
  hsa-miR-154-3p      0.1111111110
  hsa-miR-181c-3p     0.316666667
  hsa-miR-186-5p      0.223180077
  hsa-miR-190a        0.284424379
  hsa-miR-191-5p      0.262476895
  hsa-miR-199a-3p     0.255945887
  hsa-miR-199b-3p     0.255945887
  hsa-miR-21-3p       0.239819005
  hsa-miR-210         0.234042553
  hsa-miR-221-3p      0.215810131
  hsa-miR-222-3p      0.383072515
  hsa-miR-27a-5p      0.405405405
  hsa-miR-27b-3p      0.278292181
  hsa-miR-29a-3p      0.392021277
  hsa-miR-30c-2-3p    0.431818182
  hsa-miR-30d-5p      0.423982869
  hsa-miR-30e-5p      0.284369115
  hsa-miR-323a-3p     0.287449393
  hsa-miR-323b-3p     0.074626866
  hsa-miR-335-3p      0.438016529
  hsa-miR-34c-5p      0.138211382
  hsa-miR-369-3p      0.149674620
  hsa-miR-374a-5p     0.182222222
  hsa-miR-379-5p      0.346481876
  hsa-miR-411-3p      0.118299445
  hsa-miR-425-5p      0.026099925
  hsa-miR-450a-5p     0.114503817
  hsa-miR-493-5p      0.460829493
  hsa-miR-671-5p      0.326530612
  hsa-miR-708-5p      0.370967742
  hsa-miR-92a-3p      0.430016863
  hsa-miR-99b-5p      0.199426112

miR, microRNA.

###### 

Upregulated miRs in bone marrow-derived mesenchymal stem cells stimulated with PAM~3~CSK4.

  miR name          Fold change
  ----------------- --------------
  hsa-let-7a-5p     4.209545028
  hsa-let-7b-5p     6.022742040
  hsa-let-7c        3.173728814
  hsa-let-7d-5p     11.85106383
  hsa-let-7e-5p     2.807106599
  hsa-let-7f-5p     2.787247317
  hsa-let-7g-5p     2.138705416
  hsa-miR-100-5p    9.835217133
  hsa-miR-106b-5p   4.783783784
  hsa-miR-127-3p    2.286982249
  hsa-miR-1307-5p   2.181818182
  hsa-miR-130a-3p   2.319148936
  hsa-miR-136-3p    2.102564103
  hsa-miR-146a-5p   22.854166670
  hsa-miR-155-5p    5.000000000
  hsa-miR-15b-5p    3.800000000
  hsa-miR-17-3p     2.000000000
  hsa-miR-185-5p    2.1111111110
  hsa-miR-18a-5p    2.222222222
  hsa-miR-193b-3p   4.820512821
  hsa-miR-195-5p    16.080000000
  hsa-miR-196a-5p   2.655948553
  hsa-miR-214-3p    84.462585030
  hsa-miR-23a-3p    3.709433962
  hsa-miR-23b-3p    5.725806452
  hsa-miR-23c       6.500000000
  hsa-miR-24-3p     29.494703390
  hsa-miR-27b-5p    5.000000000
  hsa-miR-28-5p     2.307692308
  hsa-miR-320a      2.166666667
  hsa-miR-335-5p    2.379310345
  hsa-miR-374b-3p   4.285714286
  hsa-miR-376c-3p   2.636363636
  hsa-miR-377-3p    2.133333333
  hsa-miR-421       3.884615385
  hsa-miR-423-5p    2.112903226
  hsa-miR-424-5p    2.350000000
  hsa-miR-431-5p    3.600000000
  hsa-miR-4510      6.818181818
  hsa-miR-484       2.535714286
  hsa-miR-487b      3.000000000
  hsa-miR-493-3p    2.100000000
  hsa-miR-598       2.300000000
  hsa-miR-92b-3p    3.000000000
  hsa-miR-941       5.400000000
  hsa-miR-99a-5p    2.523255814

miR, microRNA.

[^1]: Contributed equally
